A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: T2DM (Type 2 Diabetes Mellitus)

In brief

This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus

Key facts

Study ID: NCT07321678
Run by: Ascletis Pharma (China) Co., Limited
People needed: 100
Starts: 2026-01-22
Expected to finish: 2026-08-01
Last updated by the study team: 2026-04-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have Type 2 Diabetes (T2D)
Have HbA1c ≥7.0% to ≤10.5% as determined by the central laboratory at screening.
Stable body weight (less than 5% self-reported change within the previous 3 months).
Have a BMI ≥23.0 kilogram/square meter (kg/m²) at screening.

You may not qualify if…

Have any prior diagnosis of type 1 diabetes mellitus (T1DM), or rare forms of diabetes mellitus
Have had more than 1 episode of severe hypoglycemia
Have poorly controlled hypertension
Have acute or chronic hepatitis and pancreatitis
Have evidence of a significant active and uncontrolled medical condition

Where it is running

Ascletis Clinical Site — Riverside, California, United States
Ascletis Clinical Site — San Jose, California, United States
Ascletis Clinical Site — Denver, Colorado, United States
Ascletis Clinical Site — Miami, Florida, United States
Ascletis Clinical Site — Miami, Florida, United States
Ascletis Clinical Site — Decatur, Georgia, United States
Ascletis Clinical Site — Springfield, Missouri, United States
Ascletis Clinical Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.